Cleveland BioLabs Announces Board Resignations
July 12, 2016 09:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jul 12, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that Board Chair Richard McGowan and Audit Committee Chair James Antal resigned from the company's...
Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress
May 16, 2016 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - May 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016.
...
Cleveland BioLabs Announces Webcast of Annual Meeting
April 04, 2016 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 4, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its...
Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure
March 16, 2016 14:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Mar 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an update on the regulatory review of its pre-Emergency Use Authorization (pre-EUA) submission for...
Cleveland BioLabs Reports 2015 Financial Results and Development Progress
February 22, 2016 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 22, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2015....
Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute
February 09, 2016 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 9, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic...
Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation
February 02, 2016 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 2, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the...
Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation
January 26, 2016 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 26, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as...
Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
January 21, 2016 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 21, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for...
Cleveland BioLabs and Rusnano Make Additional Investments in Panacela
December 22, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Dec 22, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO...